Gilead Sciences Gilead (NASDAQ: GILD) Gets Approval for Trodelvy in Urothelial Cancer Gilead Sciences Inc. (NASDAQ: GILD) disclosed that it has got the authorization from FDA for Trodelvy (sacituzumab govitecan-hziy) for use in grownup sufferers with locally developed or metastatic urothelial cancer (UC).
Gilead Sciences Gilead Sciences (NASDAQ: GILD) And Galapagos To Halt ISABELA Phase 3 Trial Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos (NASDAQ: GLPG) have disclosed that they both intend to stop Phase 3 clinical studies with the trial autotaxin inhibitor ziritaxestat in sufferers with idiopathic pulmonary fibrosis.
